大健康国际2020/21 年度报告

Distribution分銷Brand品牌Stock Code 股份代號: 2211UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED大健康國際集團控股有限公司UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED大健康國際集團控股有限公司(Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司）年度報告ANNUAL REPORT2020/21INTERNET+互聯網+PLATFORM+平台+SPECIALIZATION+專業+Retail零售2020/21ANNUAL REPORT年度報告UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED大健康國際集團控股有限公司 Page 頁次Company Profile 公司簡介2Corporate Information 公司資料4Financial Highlights 財務摘要6Chairman’s Statement 主席報告8Management Discussion and Analysis 管理層討論及分析13Environmental, Social and Governance Report 環境、社會及管治報告28Report of the Directors 董事會報告49Corporate Governance Report 企業管治報告71Directors and Senior Management 董事及高級管理層93Independent Auditor’s Report 獨立核數師報告103Consolidated Balance Sheet 合併資產負債表117Consolidated Statement of Comprehensive Income 合併綜合收益表119Consolidated Statement of Changes in Equity 合併權益變動表121Consolidated Cash Flow Statement 合併現金流量表123Notes to the Consolidated Financial Statements 合併財務報表附註125Financial Summary 財務資料概要263CONTENTS目錄 COMPANY PROFILE公司簡介2Universal Health International Group Holding Limited Annual Report 2020/21Universal Health International Group Holding Limited (Stock code: 2211) (the “Company”) and its subsidiaries (the “Group”) aims at huge market opportunities in the universal health industry, strives to be international brand operator of universal health and become a leading practitioner of the strategy of “Internet + Universal Health” as well as a pioneer of the development of ecology in the industry chain by way of finance and capital.The Company is one of the leading pharmaceutical retailers and distributors in the Northeast of the People’s Republic of China (the “PRC” or “China”). The Group has distinguished pharmaceutical retail chain network in the Northeast China and it is also the largest privately operated pharmaceutical distributor in the Northeast China. As of the date of this annual report, the Group operated 845 retail pharmacies, mainly located in the Northeast China, and had approximately 2,270 active distributors and 5,586 full-time staff. In addition, the Group has set up five large-scale logistics storage centers in Shijiazhuang, Shenyang, Changchun, Harbin and Jiamusi, and has established a high- quality distribution system across the country and covering the northeastern region of the PRC.As a basic business segment, the Group’s main product categories for pharmaceutical retail and distribution (including import and export trade) include prescribed drugs, non-prescribed drugs (Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs), traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, blood products, disinfection products, medical equipment, family planning supplies (contraceptives and utensils), prepackaged foods, dairy products (including infant formula milk powder), nutritional foods, health care products, stereotyped packaging cosmetics, daily necessities, etc.大健康國際集團控股有限公司（「本公司」及其附屬公司（「本集團」或「集團」），股份代號：2211），瞄準大健康領域巨大的市場機會，傾力打造國際大健康品牌運營商，並成為「互聯網+大健康」戰略的領先實踐者，和憑藉金融與資本的方式發展產業鏈生態圈的行業倡領者。本公司是中華人民共和國（「中國」）東北地區領先的醫藥零售商及分銷商之一。集團擁有中國東北地區卓越的醫藥零售連鎖網路，為中國東北地區最大的民營醫藥分銷商之一。截至本年報日期，集團擁有845家零售藥店，主要位於中國東北地區，在全國擁有約2,270名活躍分銷客戶，在職員工5,586名，並於石家莊、瀋陽、長春、哈爾濱及佳木斯設置了五個較大規模的物流儲運中心，構建了輻射全國和覆蓋中國東北地區的優質配送體系。作為基礎業務板塊，集團的醫藥零售及分銷（含進出口貿易）的主要經營產品種類，包括處方藥、非處方藥（中成藥、化學藥製劑、抗生素、生化藥品）、傳統中藥飲片、生物製品、蛋白同化製劑、肽類激素、血液製品、消毒用品、醫療器械、計生用品（避孕藥品和用具）、預包裝食品、乳製品（含嬰幼兒配方乳粉）、保健食品、保健用品、定型包裝化妝品及日用百貨等。 COMPANY PROFILE公司簡介3大健康國際集團控股有限公司 年度報告2020/21The Group will continue leveraging on the core advantages of branded products, expanding the scope of cooperation on branded products, leveraging on business institute training, and providing more value-added service to employees, customers and consumers. The Group also enriches the product mix by introducing more health care products based on the expertise in pharmaceutical retail and distribution, so as to promote the concept of the universal health industry. Meanwhile, the Group actively explores upstream ecological chain, covering the construction for Chinese herbal medicines base and the production of botanical capsule.The Group actively explores online pharmacies, cross-border e-commerce, Influencer marketing and other “Internet+” areas, and advocates the concept of “Specialization+” and introduces the development concept of “Platform+”. Furthermore, the Group maintains upstream and downstream ecosystem leveraging on industry advantage to cope with the situation of “New Norm” in real economy, and takes the lead in upgrading and digitalized transformation of the industry.集團繼續發揮品牌產品的核心優勢，擴大品牌產品合作範圍，借助商學院的課程培訓，為員工、客戶及消費者提供更多的增值服務，致力於藥品零售及分銷的專業基礎上，使更多健康類產品進入銷售管道，推行大健康行業理念。